| 163 | 0 | 62 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 分析在现代医学常规治疗基础上联合心衰宁合剂治疗阳虚水泛型射血分数降低的心力衰竭(HFr EF)的临床疗效。方法 随机选取80例HFr EF患者，采用分层随机数字表法分为观察组与对照组各40例。对照组采用标准化西药治疗，观察组在对照组治疗方案上加用心衰宁合剂，观察其临床疗效。结果 治疗后两组心功能各项指标及血清脑钠肽水平、生存质量、中医证候积分、纽约心脏病协会(NYHA)评分、尿素氮(BUN)、血清肌酐(SCr)水平均较治疗前显著改善，且观察组改善程度均显著优于对照组(P<0.05);治疗期间，两组均未出现明显不良反应。结论 心衰宁合剂联合西药治疗能够改善阳虚水泛型HFr EF患者心功能，提高生活质量，无明显不良反应。
Abstract：1中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会，等.中国心力衰竭诊断和治疗指南2024[J]．中华心血管病杂志，2024; 52(3):235-75.
2 Hao G,Wang X,Chen Z,et al.Prevalence of heart failure and left ven-tricular dysfunction in China:the China Hypertension Survey,2012-2015[J]．Eur J Heart Fail,2019; 21(11):1329-37.
3 Zhang Y,Zhang J,Butler J,et al.Contemporary epidemiology,manage-ment,and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure(China-HF) Registry[J]．J CardFail,2017; 23(12):868-75.
4 GBD 2017 Disease and Injury Incidence and Prevalence Collabora-tors. Global,regional,and national incidence,prevalence,and yearslived with disability for 354 diseases and injuries for 195 countriesand territories,1990-2017:a systematic analysis for the Global Burdenof Disease Study 2017[J]．Lancet,2018; 392(10159):1789-858.
5中华中医药学会慢性心力衰竭中医诊疗指南项目组.慢性心力衰竭中医诊疗指南(2022年)[J]．中医杂志，2023; 64(7):743-56.
6郑筱萸.中药新药临床研究指导原则(试行)[S]．北京:中国医药科技出版社，2002.
7 Mullens W,Damman K,Harjola VP,et al.The use of diuretics in heartfailure with congestion-a position statement from the Heart Failure As-sociation of the European Society of Cardiology[J]．Eur J Heart Fail,2019; 21(2):137-55.
8 Hernandez AF,Mi X,Hammill BG,et al. Associations between aldo-sterone antagonist therapy and risks of mortality and readmission a-mong patients with heart failure and reduced ejection fraction[J]．JA-MA,2012; 308(20):2097-107.
9 Guo WQ,Li L. Angiotensin converting enzyme inhibitors for heart fail-ure with reduced ejection fraction or left ventricular dysfunction:acomplementary network meta-analyses[J]．Int J Cardiol,2016; 214:10-2.
10 Cohn JN,Tognoni G. A randomized trial of the angiotensin-receptorblocker valsartan in chronic heart failure[J]．N Engl J Med,2001;345(23):1667-75.
11 Konstam MA,Neaton JD,Dickstein K,et al.Effects of high-dose ver-sus low-dose losartan on clinical outcomes in patients with heart fail-ure(HEAAL study):a randomised,double-blind trial[J]．Lancet,2009; 374(9704):1840-8.
12 Chatterjee S,Biondi-Zoccai G,Abbate A,et al.Benefits of β blockersin patients with heart failure and reduced ejection fraction:networkmeta-analysis[J]．BMJ,2013; 346:f55.
13 Velazquez EJ,Morrow DA,De Vore AD,et al.Angiotensin-neprilysininhibition in acute decompensated heart failure[J]．N Engl J Med,2019; 380(6):539-48.
14 Morrow DA,Velazquez EJ,De Vore AD,et al. Clinical outcomes inpatients with acute decompensated heart failure randomly assigned tosacubitril/valsartan or enalapril in the PIONEER-HF trial[J]．Circu-lation,2019; 139(19):2285-8.
15 Mc Murray J,Solomon SD,Inzucci SE,et al.Dapagliflozin in patientswith heart failure and reduced ejection fraction[J]．N Engl J Med,2019; 381(21):1995-2008.
16 Packer M,Anker SD,Butler J,et al. Cardiovascular and renal out-comes with empagliflozin in heart failure[J]．N Engl J Med,2020;383(15):1413-24.
17 Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patientswith heart failure and reduced ejection fraction[J]．N Engl J Med,2020; 382(20):1883-93.
18李伟.慢性充血性心力衰竭的中医研究进展[J].中西医结合心脑血管病杂志，2003; 1(4):219.
19王梦之，姚成增，王龙，等.近20年慢性心衰证候分布规律变化的文献分析[J]．时珍国医国药，2015; 26(11):2784-6.
20何远利，安祯祥，杨蕊琳，等.心衰宁颗粒治疗老年高血压病合并心力衰竭的临床研究[J]．贵阳中医学院学报，2016; 38(2):45-8.
21邓昭美，徐廉，孙刚，等.心衰宁合剂治疗冠心病缺血性心肌病型心力衰竭(心肾阳虚型)临床疗效观察[J]．贵阳中医学院学报，2014; 36(6):58-9.
22何远利，安祯祥，杨蕊琳，等.心衰宁合剂对慢性心力衰竭大鼠心肌自噬相关蛋白表达的影响[J]．中国老年学杂志，2023; 43(9):2199-204.
23何远利，安祯祥，杨蕊琳，等.心衰宁合剂对慢性心力衰竭大鼠心肌AMPK和PPARα的影响[J]．中药新药与临床药理，2020;31(3):287-93.
24 Vandenberghe W,Gevaert S,Kellum JA,et al. Acute kidney injuryin cardiorenal syndrome type 1 patients:a systematic review and me-ta-analysis[J]．Cardiorenal Med,2016; 6(2):116-28．
基本信息:
中图分类号:R259
引用信息:
[1]苏学旭,徐思思,仲秀艳,等.心衰宁合剂治疗阳虚水泛型HFrEF的临床疗效[J].中国老年学杂志,2025,45(24):5905-5909.